ISSN 1007-9327 (print) ISSN 2219-2840 (online)
World Journal of Gastroenterology World J Gastroenterol 2017 January 21; 23(3): 377-562
Published by Baishideng Publishing Group Inc
S
Weekly Volume 23 Number 3 January 21, 2017
Contents EDITORIAL 377
Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives? Cortes-Guiral D, Elias D, Cascales-Campos PA, Badía Yébenes A, Guijo Castellano I, León Carbonero AI, Martín Valadés JI, Garcia-Foncillas J, Garcia-Olmo D
REVIEW 382
Pancreatic stellate cell: Pandora’s box for pancreatic disease biology Bynigeri RR, Jakkampudi A, Jangala R, Subramanyam C, Sasikala M, Rao GV, Reddy DN, Talukdar R
MINIREVIEWS 406
Potential role of the gut microbiota in synthetic torpor and therapeutic hypothermia Sisa C, Turroni S, Amici R, Brigidi P, Candela M, Cerri M
414
Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease Tighe D, McNamara D
ORIGINAL ARTICLE Basic Study 426
Sex differences and effects of oestrogen in rat gastric mucosal defence Shore R, Björne H, Omoto Y, Siemiatkowska A, Gustafsson JÅ, Lindblad M, Holm L
437
α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease Manolakis AC, Christodoulidis G, Kapsoritakis AN, Georgoulias P, Tiaka EK, Oikonomou K, Valotassiou VJ, Potamianos SP
447
IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis Fischer S, Kövesdi E, Magyari L, Csöngei V, Hadzsiev K, Melegh B, Hegyi P, Sarlós P
455
Role of LAP+CD4+ T cells in the tumor microenvironment of colorectal cancer Zhong W, Jiang ZY, Zhang L, Huang JH, Wang SJ, Liao C, Cai B, Chen LS, Zhang S, Guo Y, Cao YF, Gao F
Retrospective Cohort Study 464
Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients Prince M, Lester L, Chiniwala R, Berger B
WJG|www.wjgnet.com
II
January 21, 2017|Volume 23|Issue 3|
World Journal of Gastroenterology
Contents 472
Volume 23 Number 3 January 21, 2017
Incidental adenocarcinoma in patients undergoing surgery for stricturing Crohn’s disease Kristo I, Riss S, Argeny S, Maschke S, Chitsabesan P, Stift A
478
Risk factors for intraoperative perforation during endoscopic submucosal dissection of superficial esophageal squamous cell carcinoma Noguchi M, Yano T, Kato T, Kadota T, Imajoh M, Morimoto H, Osera S, Yagishita A, Odagaki T, Yoda Y, Oono Y, Ikematsu H, Kaneko K
Retrospective Study 486
Macro- and microcirculation patterns of intrahepatic blood flow changes in patients with hereditary hemorrhagic telangiectasia Schelker RC, Barreiros AP, Hart C, Herr W, Jung EM
496
Prognostic factors associated with mortality in patients with gastric fundal variceal bleeding Komori K, Kubokawa M, Ihara E, Akahoshi K, Nakamura K, Motomura K, Masumoto A
505
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage Ⅲ and Ⅳ colorectal cancer Kim JH, Lee JY, Kim HK, Lee JW, Jung SG, Jung K, Kim SE, Moon W, Park MI, Park SJ
516
Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW.
Observational Study 525
Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori Bor S, Kitapcioglu G, Kasap E
533
Efficacy and safety of stellate ganglion block in chronic ulcerative colitis Zhao HY, Yang GT, Sun NN, Kong Y, Liu YF
Prospective Study 540
Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Zhang Z, Xia Y, Guo XM, Jiang GL, Zhao KL
CASE REPORT 547
First successful perinatal management of pregnancy after ABO-incompatible liver transplantation Higashi H, Obara H, Miyakoshi K, Shinoda M, Kitago M, Shimojima N, Abe Y, Hibi T, Yagi H, Matsubara K, Yamada Y, Itano O, Hoshino K, Kuroda T, Kitagawa Y
WJG|www.wjgnet.com
III
January 21, 2017|Volume 23|Issue 3|
World Journal of Gastroenterology
Contents 551
Volume 23 Number 3 January 21, 2017
Mucosa-associated lymphoid tissue lymphoma with unusual 18F-FDG hypermetabolism arising at the colorectal anastomosis Zhang NS, Shi F, Kong L, Zhu H
LETTERS TO THE EDITOR 560
Endoscopic ultrasound sedation in the United Kingdom: Is life without propofol tolerable? Campbell JA, Irvine AJ, Hopper AD
WJG|www.wjgnet.com
IV
January 21, 2017|Volume 23|Issue 3|
World Journal of Gastroenterology
Contents
Volume 23 Number 3 January 21, 2017
ABOUT COVER
Jing-Yu Deng, MD, PhD, Associate Professor, Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital and City Key Laboratory of Tianjin Cancer Center, Tianjin 300060, China
AIMS AND SCOPE
World Journal of Gastroenterology (World J Gastroenterol, WJG, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. WJG was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The WJG Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries. The primary task of WJG is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. WJG is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.
INDEXING/ABSTRACTING
World Journal of Gastroenterology (WJG) is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports® released by Thomson Reuters (ISI) cites the 2015 impact factor for WJG as 2.787 (5-year impact factor: 2.848), ranking WJG as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).
FLYLEAF
I-IX
Editorial Board
ED TH
NAM Worl
ISSN ISSN ISSN
EDITORS FOR THIS ISSUE
Responsible Assistant Editor: Xiang Li Responsible Electronic Editor: Wen-Xi Liu Proofing Editor-in-Chief: Lian-Sheng Ma
NAME OF JOURNAL World Journal of Gastroenterology ISSN ISSN 1007-9327 (print) ISSN 2219-2840 (online) LAUNCH DATE October 1, 1995 FREQUENCY Weekly EDITORS-IN-CHIEF Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,
WJG|www.wjgnet.com
Responsible Science Editor: Yuan Qi Proofing Editorial Office Director: Jin-Lei Wang
CA 90822, United States
http://www.wjgnet.com
EDITORIAL BOARD MEMBERS All editorial board members resources online at http:// www.wjgnet.com/1007-9327/editorialboard.htm
PUBLICATION DATE January 21, 2017
EDITORIAL OFFICE Jin-Lei Wang, Director Yuan Qi, Vice Director Ze-Mao Gong, Vice Director World Journal of Gastroenterology Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-2238242 Fax: +1-925-2238243 E-mail: [email protected] Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com PUBLISHER Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-2238242 Fax: +1-925-2238243 E-mail: [email protected] Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
0018
COPYRIGHT © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. SPECIAL STATEMENT All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated. INSTRUCTIONS TO AUTHORS Full instructions are available online at http://www. wjgnet.com/bpg/gerinfo/204 ONLINE SUBMISSION http://www.wjgnet.com/esps/
January 21, 2017|Volume 23|Issue 3|
LAU Octo
FRE Wee
EDI Dam sor, Auto gery Mad
Step Labo linsk
And Prof Lon
World J Gastroenterol 2017 January 21; 23(3): 560-562 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v23.i3.560
© 2017 Baishideng Publishing Group Inc. All rights reserved.
LETTERS TO THE EDITOR
Endoscopic ultrasound sedation in the United Kingdom: Is life without propofol tolerable? Jennifer Anne Campbell, Andrew James Irvine, Andrew Derek Hopper cost effectiveness and safety profile of non-anesthe siologist-administered propofol for endoscopic ultra sound (EUS). However in the United Kingdom, it is recommended that the administration and monitoring of propofol sedation for endoscopic procedures should be the responsibility of a dedicated and appropriately trained anaesthetist only. The majority of United Kingdom EUS procedures are performed with opiate and benzodiazepine sedation rather than anaesthetist led propofol lists due to anaesthetist resource avail ability. We sought to prospectively determine the tolerability and safety of EUS with benzodiazepine and opiate sedation in single United Kingdom centre. Two hundred consecutive patients undergoing either EUS or oesophago-gastroduodenoscopy (OGD) with conscious sedation were prospectively recruited with a 1:1 enrolment ratio. Patients completed questionnaires pre and post procedure detailing anticipated and actual pain experienced on a 1-10 visual analogue scale. Demographics, procedure duration, sedation doses and willingness to repeat the procedure were also recorded. EUS procedures lasted significantly longer than OGDs (15 min vs 6 min, P < 0.0001), however, there was no difference in anticipated pain scores between the groups (EUS 3.37/10 vs OGD 3.47/10, P = 0.46). Pain scores indicated EUS was better tolerated than OGD (1.16/10 vs 1.88/10, P = 0.03) although higher doses of sedation were used for EUS procedures. There were no complications identified in either group. We feel our study demonstrates that the tolerability of EUS with opiate and benzodiazepine sedation is acceptable.
Jennifer Anne Campbell, Andrew James Irvine, Andrew Derek Hopper, Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield S10 2JF, United Kingdom Author contributions: Campbell JA wrote this letter, analysed and interpreted data; Irvine AJ and Hopper AD contributed to conception and design of the study, acquisition of data, and analysis and interpretation of data and approved the final version of the article to be published. Conflict-of-interest statement: All authors are employed by Sheffield Teaching Hospitals NHS Foundation Trust. No funding was required for this study and there are no competing interests to declare. Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons. org/licenses/by-nc/4.0/ Manuscript source: Unsolicited manuscript Correspondence to: Jennifer A Campbell, Department of Gastroenterology, Royal Hallamshire Hospital, Room P39, Glossop Road, Sheffield S10 2JF, United Kingdom. [email protected] Telephone: +44-114-2712353 Fax: +44-114-2712692 Received: October 4, 2016 Peer-review started: October 7, 2016 First decision: November 9, 2016 Revised: November 15, 2016 Accepted: December 2, 2016 Article in press: December 2, 2016 Published online: January 21, 2017
Key words: Sedation; Endoscopy; Tolerability; Propofol; Endoscopic ultrasound © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Strong evidence exists to support safety and tolerability of non-anaesthesiologist-administered propofol for endoscopic ultrasound (EUS) procedures. United Kingdom guidelines, however, recommend
Abstract There is compelling evidence to support the quality, WJG|www.wjgnet.com
560
January 21, 2017|Volume 23|Issue 3|
Campbell JA et al . Endoscopic ultrasound sedation in the United Kingdom
propofol is administered only by anaesthesiologists. Consequently, in the United Kingdom, nearly all EUS procedures are performed with combinations of benzodiazepine and opiate sedation for which little tolerability data exists. This letter shares the experience of a single EUS centre using benzodiazepine and opiate sedation demonstrating it can be safe and the resulting tolerability acceptable.
Table 1 Comparison of patients undergoing sedated endoscopic ultrasound and oesophago-gastroduodenoscopy procedures n (%)
Age, yr (range) Female Median duration minutes (range) Average midazolam mg (range) Average fentanyl mcg (range) Procedures using fentanyl and midazolam Mean expected pain 1-10 (SD) Mean actual pain 1-10 (SD) Would you have the test again? Complications recorded
Campbell JA, Irvine AJ, Hopper AD. Endoscopic ultrasound sedation in the United Kingdom: Is life without propofol tolerable? World J Gastroenterol 2017; 23(3): 560-562 Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i3/560. htm DOI: http://dx.doi.org/10.3748/wjg.v23.i3.560
OGD
EUS
n =100
n =100
P value
52.5 (17-85) 63 (22-90) 69 53 6 (2-33) 15 (6-38) 3 (1-15) 4 (1-8) 75 (50-150) 100 (25-200) 6% 67%
P < 0.0001 P = 0.001 P < 0.0001 P < 0.0001
3.47 (2.80) 1.88 (2.61) 87 0
P = 0.46 P = 0.03 P = 0.15 -
3.37 (2.70) 1.16 (1.99) 94 0
OGD: Oesophago-gastroduodenoscopy; EUS: Endoscopic ultrasound.
TO THE EDITOR to repeat the procedure was also noted. Procedure duration and sedation dosages were recorded for each patient. Sedation complications were regarded as use of intravenous reversal agents and or assisted ventilation. Fisher’s test was used to generate P values comparing the means of groups for age, duration, drug doses and pain scores. Unpaired t-test was used to calculate P values for willingness to have a repeat procedure. Two hundred consecutive patients undergoing either OGD (100) or EUS (100) were recruited (Table 1). All procedures were completed and no significant difference in expected pain scores between the OGD and EUS groups were observed (P = 0.46). EUS procedures lasted significantly longer than OGDs (15 min vs 6 min, P < 0.0001) and used significantly higher doses of both midazolam (P = 0.001) and fentanyl (P < 0.0001). Patients undergoing EUS were significantly more likely to receive fentanyl and midazolam in combination compared to those having ODG (67% vs 6%, P < 0.0001). Despite the increased procedure time in the EUS group, the sedation used resulted in significantly lower pain scores for EUS compared to OGD (1.16/10 vs 1.88/10, P = 0.03). Assisted ventilation was not required and no intravenous sedation reversal agents were used in either group. In conclusion, although propofol has been shown to be a superior sedation agent the mandatory anaesthetic support required in the United Kingdom makes its unfeasible to be used for all EUS procedures. We feel our study demonstrates that the tolerability of EUS with opiate and benzodiazepine sedation is acceptable.
We read with interest the review by Cheriyan and Byrne analysing the benefits of propofol sedation in advanced endoscopic procedures and endoscopic [1] ultrasound (EUS) . Whilst we agree that there is compelling evidence to support the quality, cost effectiveness and safety profile of non-anaesthesiologistadministered propofol (NAAP) for EUS (including [1-3] gastroenterologist and nurse administration) , there are current restrictions in the United Kingdom which make NAAP difficult to implement for all EUS procedures. Propofol can produce transient apnoea or general anaesthesia for which there is no reversal agent, therefore the United Kingdom joint anaesthetic and gastroenterology guidelines recommend that propofol administration for complex endoscopic procedures should be the responsibility of dedicated anaesthetists [4] only . Demand for EUS in the United Kingdom is increasing and as a consequence, it is not feasible for all EUS procedures to be performed with anaesthesiologist administration. The vast majority are carried out using combination opiate and benzodiazepine sedation. Although a number of studies have sought to assess tolerability of gastroscopy and colonoscopy with [5-7] benzodiazepine and opiate sedation this has rarely [8,9] included EUS . EUS procedures take longer and use larger diameter endoscopes (13.8-14.6 mm) compared to conventional oesophago-gastroduodenoscopy (OGD) (9.9-10.2 mm). It is important to ensure that EUS tolerability is acceptable. We prospectively examined outcomes in a single EUS centre in the United Kingdom to assess if the tolerability of sedated EUS was comparable to sedated OGD. Consecutive patients undergoing EUS or OGD with sedation (either midazolam and or fentanyl) were prospectively identified with a 1:1 enrolment ratio. After being counselled and consented, patients were asked to complete pre and post procedure questionnaires. A visual analogue scale (0-10) was used to record patients’ expected pain pre-procedure and the actual pain perceived post-procedure. Subsequent willingness
WJG|www.wjgnet.com
REFERENCES 1
2
561
Cheriyan DG, Byrne MF. Propofol use in endoscopic retrograde cholangiopancreatography and endoscopic ultrasound. World J Gastroenterol 2014; 20: 5171-5176 [PMID: 24833847 DOI: 10.3748/wjg.v20.i18.5171] Fatima H, DeWitt J, LeBlanc J, Sherman S, McGreevy K, Imperiale TF. Nurse-administered propofol sedation for upper endoscopic ultrasonography. Am J Gastroenterol 2008; 103: 1649-1656
January 21, 2017|Volume 23|Issue 3|
Campbell JA et al . Endoscopic ultrasound sedation in the United Kingdom
3
4
5
[PMID: 18557709 DOI: 10.1111/j1572-0241.2008.01906.x] Nayar DS, Guthrie WG, Goodman A, Lee Y, Feuerman M, Scheinberg L, Gress FG. Comparison of propofol deep sedation versus moderate sedation during endosonography. Dig Dis Sci 2010; 55: 2537-2544 [PMID: 20635148 DOI: 10.1007/s10620 -010-1308-0] Tomlinson A, Green J, Cairns SR, Cressey D, Smith, I, Peacock J. Guidance for the use of propofol sedation for adult patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) and other complex upper GI endoscopic procedures. On behalf of the Joint Royal College of Anaesthetists (RCoA) and British Society of Gastroenterology (BSG) Working Part. Available from: URL: http://www.bsg.org.uk/clinical-guidance/endoscopy/ guidance-for-the-use-of-propofol-sedation-for-adults-undergoingendoscopic-retrograde-cholangiopancreatography-ercp.html Ko HH, Zhang H, Telford JJ, Enns R. Factors influencing patient satisfaction when undergoing endoscopic procedures. Gastrointest Endosc 2009; 69: 883-891, quiz 891.e1 [PMID: 19152911 DOI:
6
7 8
9
10.1016/j.gie.2008.06.024] Peña LR, Mardini HE, Nickl NJ. Development of an instrument to assess and predict satisfaction and poor tolerance among patients undergoing endoscopic procedures. Dig Dis Sci 2005; 50: 1860-1871 [PMID: 16187188 DOI: 10.1007/s10620-005-2952-7] Salmon P, Shah R, Berg S, Williams C. Evaluating customer satisfaction with colonoscopy. Endoscopy 1994; 26: 342-346 [PMID: 8076565 DOI: 10.1055/s-2007-1008988] Dewitt J, McGreevy K, Sherman S, Imperiale TF. Nurseadministered propofol sedation compared with midazolam and meperidine for EUS: a prospective, randomized trial. Gastrointest Endosc 2008; 68: 499-509 [PMID: 18561925 DOI: 10.1016/j. gie.2008.02.092] Mortensen MB, Fristrup C, Holm FS, Pless T, Durup J, Ainsworth AP, Nielsen HO, Hovendal C. Prospective evaluation of patient tolerability, satisfaction with patient information, and complications in endoscopic ultrasonography. Endoscopy 2005; 37: 146-153 [PMID: 15692930 DOI: 10.1055/s-2005-861142] P- Reviewer: Corrales FJJ, Fargion S, Morales-Ruiz M S- Editor: Qi Y L- Editor: A E- Editor: Liu WX
WJG|www.wjgnet.com
562
January 21, 2017|Volume 23|Issue 3|
Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: [email protected] Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com
I S S N 1 0 0 7 - 9 3 2 7 0 3
9 7 7 1 0 0 7 9 3 2 0 45 © 2016 Baishideng Publishing Group Inc. All rights reserved.
World Journal of Gastroenterology World J Gastroenterol 2017 January 21; 23(3): 377-562
Published by Baishideng Publishing Group Inc
S
Weekly Volume 23 Number 3 January 21, 2017
Contents EDITORIAL 377
Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives? Cortes-Guiral D, Elias D, Cascales-Campos PA, Badía Yébenes A, Guijo Castellano I, León Carbonero AI, Martín Valadés JI, Garcia-Foncillas J, Garcia-Olmo D
REVIEW 382
Pancreatic stellate cell: Pandora’s box for pancreatic disease biology Bynigeri RR, Jakkampudi A, Jangala R, Subramanyam C, Sasikala M, Rao GV, Reddy DN, Talukdar R
MINIREVIEWS 406
Potential role of the gut microbiota in synthetic torpor and therapeutic hypothermia Sisa C, Turroni S, Amici R, Brigidi P, Candela M, Cerri M
414
Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease Tighe D, McNamara D
ORIGINAL ARTICLE Basic Study 426
Sex differences and effects of oestrogen in rat gastric mucosal defence Shore R, Björne H, Omoto Y, Siemiatkowska A, Gustafsson JÅ, Lindblad M, Holm L
437
α2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease Manolakis AC, Christodoulidis G, Kapsoritakis AN, Georgoulias P, Tiaka EK, Oikonomou K, Valotassiou VJ, Potamianos SP
447
IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis Fischer S, Kövesdi E, Magyari L, Csöngei V, Hadzsiev K, Melegh B, Hegyi P, Sarlós P
455
Role of LAP+CD4+ T cells in the tumor microenvironment of colorectal cancer Zhong W, Jiang ZY, Zhang L, Huang JH, Wang SJ, Liao C, Cai B, Chen LS, Zhang S, Guo Y, Cao YF, Gao F
Retrospective Cohort Study 464
Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients Prince M, Lester L, Chiniwala R, Berger B
WJG|www.wjgnet.com
II
January 21, 2017|Volume 23|Issue 3|
World Journal of Gastroenterology
Contents 472
Volume 23 Number 3 January 21, 2017
Incidental adenocarcinoma in patients undergoing surgery for stricturing Crohn’s disease Kristo I, Riss S, Argeny S, Maschke S, Chitsabesan P, Stift A
478
Risk factors for intraoperative perforation during endoscopic submucosal dissection of superficial esophageal squamous cell carcinoma Noguchi M, Yano T, Kato T, Kadota T, Imajoh M, Morimoto H, Osera S, Yagishita A, Odagaki T, Yoda Y, Oono Y, Ikematsu H, Kaneko K
Retrospective Study 486
Macro- and microcirculation patterns of intrahepatic blood flow changes in patients with hereditary hemorrhagic telangiectasia Schelker RC, Barreiros AP, Hart C, Herr W, Jung EM
496
Prognostic factors associated with mortality in patients with gastric fundal variceal bleeding Komori K, Kubokawa M, Ihara E, Akahoshi K, Nakamura K, Motomura K, Masumoto A
505
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with stage Ⅲ and Ⅳ colorectal cancer Kim JH, Lee JY, Kim HK, Lee JW, Jung SG, Jung K, Kim SE, Moon W, Park MI, Park SJ
516
Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW.
Observational Study 525
Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori Bor S, Kitapcioglu G, Kasap E
533
Efficacy and safety of stellate ganglion block in chronic ulcerative colitis Zhao HY, Yang GT, Sun NN, Kong Y, Liu YF
Prospective Study 540
Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma Zhu HT, Ai DS, Tang HR, Badakhshi H, Fan JH, Deng JY, Zhang JH, Chen Y, Zhang Z, Xia Y, Guo XM, Jiang GL, Zhao KL
CASE REPORT 547
First successful perinatal management of pregnancy after ABO-incompatible liver transplantation Higashi H, Obara H, Miyakoshi K, Shinoda M, Kitago M, Shimojima N, Abe Y, Hibi T, Yagi H, Matsubara K, Yamada Y, Itano O, Hoshino K, Kuroda T, Kitagawa Y
WJG|www.wjgnet.com
III
January 21, 2017|Volume 23|Issue 3|
World Journal of Gastroenterology
Contents 551
Volume 23 Number 3 January 21, 2017
Mucosa-associated lymphoid tissue lymphoma with unusual 18F-FDG hypermetabolism arising at the colorectal anastomosis Zhang NS, Shi F, Kong L, Zhu H
LETTERS TO THE EDITOR 560
Endoscopic ultrasound sedation in the United Kingdom: Is life without propofol tolerable? Campbell JA, Irvine AJ, Hopper AD
WJG|www.wjgnet.com
IV
January 21, 2017|Volume 23|Issue 3|
World Journal of Gastroenterology
Contents
Volume 23 Number 3 January 21, 2017
ABOUT COVER
Jing-Yu Deng, MD, PhD, Associate Professor, Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital and City Key Laboratory of Tianjin Cancer Center, Tianjin 300060, China
AIMS AND SCOPE
World Journal of Gastroenterology (World J Gastroenterol, WJG, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. WJG was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The WJG Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries. The primary task of WJG is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. WJG is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.
INDEXING/ABSTRACTING
World Journal of Gastroenterology (WJG) is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports® released by Thomson Reuters (ISI) cites the 2015 impact factor for WJG as 2.787 (5-year impact factor: 2.848), ranking WJG as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).
FLYLEAF
I-IX
Editorial Board
ED TH
NAM Worl
ISSN ISSN ISSN
EDITORS FOR THIS ISSUE
Responsible Assistant Editor: Xiang Li Responsible Electronic Editor: Wen-Xi Liu Proofing Editor-in-Chief: Lian-Sheng Ma
NAME OF JOURNAL World Journal of Gastroenterology ISSN ISSN 1007-9327 (print) ISSN 2219-2840 (online) LAUNCH DATE October 1, 1995 FREQUENCY Weekly EDITORS-IN-CHIEF Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,
WJG|www.wjgnet.com
Responsible Science Editor: Yuan Qi Proofing Editorial Office Director: Jin-Lei Wang
CA 90822, United States
http://www.wjgnet.com
EDITORIAL BOARD MEMBERS All editorial board members resources online at http:// www.wjgnet.com/1007-9327/editorialboard.htm
PUBLICATION DATE January 21, 2017
EDITORIAL OFFICE Jin-Lei Wang, Director Yuan Qi, Vice Director Ze-Mao Gong, Vice Director World Journal of Gastroenterology Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-2238242 Fax: +1-925-2238243 E-mail: [email protected] Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com PUBLISHER Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-2238242 Fax: +1-925-2238243 E-mail: [email protected] Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
0018
COPYRIGHT © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. SPECIAL STATEMENT All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated. INSTRUCTIONS TO AUTHORS Full instructions are available online at http://www. wjgnet.com/bpg/gerinfo/204 ONLINE SUBMISSION http://www.wjgnet.com/esps/
January 21, 2017|Volume 23|Issue 3|
LAU Octo
FRE Wee
EDI Dam sor, Auto gery Mad
Step Labo linsk
And Prof Lon
World J Gastroenterol 2017 January 21; 23(3): 560-562 ISSN 1007-9327 (print) ISSN 2219-2840 (online)
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v23.i3.560
© 2017 Baishideng Publishing Group Inc. All rights reserved.
LETTERS TO THE EDITOR
Endoscopic ultrasound sedation in the United Kingdom: Is life without propofol tolerable? Jennifer Anne Campbell, Andrew James Irvine, Andrew Derek Hopper cost effectiveness and safety profile of non-anesthe siologist-administered propofol for endoscopic ultra sound (EUS). However in the United Kingdom, it is recommended that the administration and monitoring of propofol sedation for endoscopic procedures should be the responsibility of a dedicated and appropriately trained anaesthetist only. The majority of United Kingdom EUS procedures are performed with opiate and benzodiazepine sedation rather than anaesthetist led propofol lists due to anaesthetist resource avail ability. We sought to prospectively determine the tolerability and safety of EUS with benzodiazepine and opiate sedation in single United Kingdom centre. Two hundred consecutive patients undergoing either EUS or oesophago-gastroduodenoscopy (OGD) with conscious sedation were prospectively recruited with a 1:1 enrolment ratio. Patients completed questionnaires pre and post procedure detailing anticipated and actual pain experienced on a 1-10 visual analogue scale. Demographics, procedure duration, sedation doses and willingness to repeat the procedure were also recorded. EUS procedures lasted significantly longer than OGDs (15 min vs 6 min, P < 0.0001), however, there was no difference in anticipated pain scores between the groups (EUS 3.37/10 vs OGD 3.47/10, P = 0.46). Pain scores indicated EUS was better tolerated than OGD (1.16/10 vs 1.88/10, P = 0.03) although higher doses of sedation were used for EUS procedures. There were no complications identified in either group. We feel our study demonstrates that the tolerability of EUS with opiate and benzodiazepine sedation is acceptable.
Jennifer Anne Campbell, Andrew James Irvine, Andrew Derek Hopper, Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield S10 2JF, United Kingdom Author contributions: Campbell JA wrote this letter, analysed and interpreted data; Irvine AJ and Hopper AD contributed to conception and design of the study, acquisition of data, and analysis and interpretation of data and approved the final version of the article to be published. Conflict-of-interest statement: All authors are employed by Sheffield Teaching Hospitals NHS Foundation Trust. No funding was required for this study and there are no competing interests to declare. Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons. org/licenses/by-nc/4.0/ Manuscript source: Unsolicited manuscript Correspondence to: Jennifer A Campbell, Department of Gastroenterology, Royal Hallamshire Hospital, Room P39, Glossop Road, Sheffield S10 2JF, United Kingdom. [email protected] Telephone: +44-114-2712353 Fax: +44-114-2712692 Received: October 4, 2016 Peer-review started: October 7, 2016 First decision: November 9, 2016 Revised: November 15, 2016 Accepted: December 2, 2016 Article in press: December 2, 2016 Published online: January 21, 2017
Key words: Sedation; Endoscopy; Tolerability; Propofol; Endoscopic ultrasound © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Strong evidence exists to support safety and tolerability of non-anaesthesiologist-administered propofol for endoscopic ultrasound (EUS) procedures. United Kingdom guidelines, however, recommend
Abstract There is compelling evidence to support the quality, WJG|www.wjgnet.com
560
January 21, 2017|Volume 23|Issue 3|
Campbell JA et al . Endoscopic ultrasound sedation in the United Kingdom
propofol is administered only by anaesthesiologists. Consequently, in the United Kingdom, nearly all EUS procedures are performed with combinations of benzodiazepine and opiate sedation for which little tolerability data exists. This letter shares the experience of a single EUS centre using benzodiazepine and opiate sedation demonstrating it can be safe and the resulting tolerability acceptable.
Table 1 Comparison of patients undergoing sedated endoscopic ultrasound and oesophago-gastroduodenoscopy procedures n (%)
Age, yr (range) Female Median duration minutes (range) Average midazolam mg (range) Average fentanyl mcg (range) Procedures using fentanyl and midazolam Mean expected pain 1-10 (SD) Mean actual pain 1-10 (SD) Would you have the test again? Complications recorded
Campbell JA, Irvine AJ, Hopper AD. Endoscopic ultrasound sedation in the United Kingdom: Is life without propofol tolerable? World J Gastroenterol 2017; 23(3): 560-562 Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i3/560. htm DOI: http://dx.doi.org/10.3748/wjg.v23.i3.560
OGD
EUS
n =100
n =100
P value
52.5 (17-85) 63 (22-90) 69 53 6 (2-33) 15 (6-38) 3 (1-15) 4 (1-8) 75 (50-150) 100 (25-200) 6% 67%
P < 0.0001 P = 0.001 P < 0.0001 P < 0.0001
3.47 (2.80) 1.88 (2.61) 87 0
P = 0.46 P = 0.03 P = 0.15 -
3.37 (2.70) 1.16 (1.99) 94 0
OGD: Oesophago-gastroduodenoscopy; EUS: Endoscopic ultrasound.
TO THE EDITOR to repeat the procedure was also noted. Procedure duration and sedation dosages were recorded for each patient. Sedation complications were regarded as use of intravenous reversal agents and or assisted ventilation. Fisher’s test was used to generate P values comparing the means of groups for age, duration, drug doses and pain scores. Unpaired t-test was used to calculate P values for willingness to have a repeat procedure. Two hundred consecutive patients undergoing either OGD (100) or EUS (100) were recruited (Table 1). All procedures were completed and no significant difference in expected pain scores between the OGD and EUS groups were observed (P = 0.46). EUS procedures lasted significantly longer than OGDs (15 min vs 6 min, P < 0.0001) and used significantly higher doses of both midazolam (P = 0.001) and fentanyl (P < 0.0001). Patients undergoing EUS were significantly more likely to receive fentanyl and midazolam in combination compared to those having ODG (67% vs 6%, P < 0.0001). Despite the increased procedure time in the EUS group, the sedation used resulted in significantly lower pain scores for EUS compared to OGD (1.16/10 vs 1.88/10, P = 0.03). Assisted ventilation was not required and no intravenous sedation reversal agents were used in either group. In conclusion, although propofol has been shown to be a superior sedation agent the mandatory anaesthetic support required in the United Kingdom makes its unfeasible to be used for all EUS procedures. We feel our study demonstrates that the tolerability of EUS with opiate and benzodiazepine sedation is acceptable.
We read with interest the review by Cheriyan and Byrne analysing the benefits of propofol sedation in advanced endoscopic procedures and endoscopic [1] ultrasound (EUS) . Whilst we agree that there is compelling evidence to support the quality, cost effectiveness and safety profile of non-anaesthesiologistadministered propofol (NAAP) for EUS (including [1-3] gastroenterologist and nurse administration) , there are current restrictions in the United Kingdom which make NAAP difficult to implement for all EUS procedures. Propofol can produce transient apnoea or general anaesthesia for which there is no reversal agent, therefore the United Kingdom joint anaesthetic and gastroenterology guidelines recommend that propofol administration for complex endoscopic procedures should be the responsibility of dedicated anaesthetists [4] only . Demand for EUS in the United Kingdom is increasing and as a consequence, it is not feasible for all EUS procedures to be performed with anaesthesiologist administration. The vast majority are carried out using combination opiate and benzodiazepine sedation. Although a number of studies have sought to assess tolerability of gastroscopy and colonoscopy with [5-7] benzodiazepine and opiate sedation this has rarely [8,9] included EUS . EUS procedures take longer and use larger diameter endoscopes (13.8-14.6 mm) compared to conventional oesophago-gastroduodenoscopy (OGD) (9.9-10.2 mm). It is important to ensure that EUS tolerability is acceptable. We prospectively examined outcomes in a single EUS centre in the United Kingdom to assess if the tolerability of sedated EUS was comparable to sedated OGD. Consecutive patients undergoing EUS or OGD with sedation (either midazolam and or fentanyl) were prospectively identified with a 1:1 enrolment ratio. After being counselled and consented, patients were asked to complete pre and post procedure questionnaires. A visual analogue scale (0-10) was used to record patients’ expected pain pre-procedure and the actual pain perceived post-procedure. Subsequent willingness
WJG|www.wjgnet.com
REFERENCES 1
2
561
Cheriyan DG, Byrne MF. Propofol use in endoscopic retrograde cholangiopancreatography and endoscopic ultrasound. World J Gastroenterol 2014; 20: 5171-5176 [PMID: 24833847 DOI: 10.3748/wjg.v20.i18.5171] Fatima H, DeWitt J, LeBlanc J, Sherman S, McGreevy K, Imperiale TF. Nurse-administered propofol sedation for upper endoscopic ultrasonography. Am J Gastroenterol 2008; 103: 1649-1656
January 21, 2017|Volume 23|Issue 3|
Campbell JA et al . Endoscopic ultrasound sedation in the United Kingdom
3
4
5
[PMID: 18557709 DOI: 10.1111/j1572-0241.2008.01906.x] Nayar DS, Guthrie WG, Goodman A, Lee Y, Feuerman M, Scheinberg L, Gress FG. Comparison of propofol deep sedation versus moderate sedation during endosonography. Dig Dis Sci 2010; 55: 2537-2544 [PMID: 20635148 DOI: 10.1007/s10620 -010-1308-0] Tomlinson A, Green J, Cairns SR, Cressey D, Smith, I, Peacock J. Guidance for the use of propofol sedation for adult patients undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) and other complex upper GI endoscopic procedures. On behalf of the Joint Royal College of Anaesthetists (RCoA) and British Society of Gastroenterology (BSG) Working Part. Available from: URL: http://www.bsg.org.uk/clinical-guidance/endoscopy/ guidance-for-the-use-of-propofol-sedation-for-adults-undergoingendoscopic-retrograde-cholangiopancreatography-ercp.html Ko HH, Zhang H, Telford JJ, Enns R. Factors influencing patient satisfaction when undergoing endoscopic procedures. Gastrointest Endosc 2009; 69: 883-891, quiz 891.e1 [PMID: 19152911 DOI:
6
7 8
9
10.1016/j.gie.2008.06.024] Peña LR, Mardini HE, Nickl NJ. Development of an instrument to assess and predict satisfaction and poor tolerance among patients undergoing endoscopic procedures. Dig Dis Sci 2005; 50: 1860-1871 [PMID: 16187188 DOI: 10.1007/s10620-005-2952-7] Salmon P, Shah R, Berg S, Williams C. Evaluating customer satisfaction with colonoscopy. Endoscopy 1994; 26: 342-346 [PMID: 8076565 DOI: 10.1055/s-2007-1008988] Dewitt J, McGreevy K, Sherman S, Imperiale TF. Nurseadministered propofol sedation compared with midazolam and meperidine for EUS: a prospective, randomized trial. Gastrointest Endosc 2008; 68: 499-509 [PMID: 18561925 DOI: 10.1016/j. gie.2008.02.092] Mortensen MB, Fristrup C, Holm FS, Pless T, Durup J, Ainsworth AP, Nielsen HO, Hovendal C. Prospective evaluation of patient tolerability, satisfaction with patient information, and complications in endoscopic ultrasonography. Endoscopy 2005; 37: 146-153 [PMID: 15692930 DOI: 10.1055/s-2005-861142] P- Reviewer: Corrales FJJ, Fargion S, Morales-Ruiz M S- Editor: Qi Y L- Editor: A E- Editor: Liu WX
WJG|www.wjgnet.com
562
January 21, 2017|Volume 23|Issue 3|
Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: [email protected] Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com
I S S N 1 0 0 7 - 9 3 2 7 0 3
9 7 7 1 0 0 7 9 3 2 0 45 © 2016 Baishideng Publishing Group Inc. All rights reserved.
The World Journal of Gastroenterology (WJG) is an academic journal that publishes review articles and articles describing original research (basic or clinical) in the fields of gastroenterology, hepatology, gastrointestinal surgery, and gastrointestinal endoscopy.With the aim of advancing knowledge in each of these fields, the WJG gives topical priority to related major diseases and their.